Gilead completes $7.8B Arcellx acquisition & takes full control of Myeloma CAR-T candidate
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Subscribe To Our Newsletter & Stay Updated